Skip to main content

Table 3 Adherence, quality of life and psychopathology measurements of the patients

From: Adherence to medical treatment for Wilson’s disease in children and adolescents: a cohort study from Turkey

Scales

Onset of treatment

MARS-5, mean (SD)

20.67 (4.55)

Non-adherence at a cut-off of < 20, n (%)

7 (23.3)

MPR, median (range)

D-penicillamine (n = 27)

0.96 (0–1.00)

Non-adherence at a cut-off of ≥ 20%, n (%)

8 (29.6)

Trientine (n = 3)

0.89 (0.83–0.99)

Non-adherence at a cut-off of ≥ 20%, n (%)

Zinc (n = 29)

0.93 (0–1.00)

Non-adherence at a cut-off of ≥ 20%, n (%)

5 (17.2)

Pyridoxine (vitamin B6) (n = 19)

1.00 (0.03–1.00)

Non-adherence at a cut-off of ≥ 20%, n (%)

1 (5.3)

PedsQL for Children, mean (SD)

21.60 (13.40)

PedsQL for Parents, mean (SD)

19.30 (11.78)

Childhood Depression Inventory, mean (SD)

7.07 (5.81)

State trait anxiety inventory for children, mean (SD)

State Anxiety

33.30 (10.55)

Trait Anxiety

36.97 (11.17)

  1. MARS-5: The Medication Adherence Report Scale, SD: Standard deviation, MPR: Medication Possession Ratio, PedsQL: The Pediatric Quality of Life Inventory